December #42 : Therapeutic Vaccine in the Works - by Lark Lands, PhD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

The Age of Ignorance

Reboot Your System

POZ Annual Givers Guide

POZ Annual Givers Guide, Part 2

A Happy Convert

Working Mom

Money Man

You Can Take It With You

LifeStyle Change

Mom Knows Best

Foul Ball


To the Editor


Don't Ask, Do Tell?

In Your Wildest Steams

Boys in Green

When This You See

Ab-Fab Babs

Say What

POZarazzi: Random Harvest

Pirate of Penance

Show and Tell

hiv and Me

How Am I?

A Bite of the Apple

Down-and-Dirty Markups

Grow Your Own Bacteria

The Rx Files

Beyond Grapefruit Juice

Douching Dangers

Therapeutic Vaccine in the Works

A B.i.d. for Easier Adherence

Nevirapine for Best Head

Strong in the Tooth

Buyers Clubs

Where to Find It

Pair of Aces

Aunt Evelyn's Letters

POZ Picks

Letter from Sri Lanka: Island Fever

Wrong Way on the ADA

Mann of the Hour


Talk to the Hand

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 1998

Therapeutic Vaccine in the Works

by Lark Lands, PhD

Science often seems to offer little hope to HIVers in poorer countries or those unable to tolerate current regimens. But Robert Gallo, MD, director of the University of Maryland’s Institute of Human Virology, is out to change all that. Pursuing research by the University of Paris’ Daniel Zagury, Gallo and his team are working with Zagury and others in Italy, Israel, France and the United States to open up a new avenue of treatment: a therapeutic vaccine that will suppress both interferon-alpha (an between-cell chemical messenger) and HIV tat (a protein released by the virus).

Research has shown that both of these chemicals not only inhibit T-cell proliferation but promote the expansion of immunosuppressive CD8 cells, thus undermining the immune system’s ability to control HIV. Pilot studies using the vaccine in about 70 people at various disease stages have found a significant reduction in the level of both chemicals, as well as a modest drop in viral load.

Although Gallo and Zagury don’t think the vaccine will work as well as HAART in decreasing high viral loads, they predict that early use might stabilize CD4 counts and improve immune function, postponing the need for antiretrovirals. The treatment could also be a last-ditch option for those whose drugs have failed. And since the vaccine would be inexpensive and probably only needed a few times a year, it might be the first therapy available to the 95 percent of the world’s PWAs for whom five-figure HAART is out of reach. A U.S. trial should begin by early 1999. Stay tuned.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.